Drug
D0062 | Flutamide
L
L02BB01 Flutamide
[L02BB] Anti-androgens
[L02B] HORMONE ANTAGONISTS AND RELATED AGENTS
[L02] ENDOCRINE THERAPY
[L] Antineoplastic and immunomodulating agents
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 27 µM | 30 mins | mouse | liver mitochondria | Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) | decrease | EC20 | 36 |
| RESPIRATION | ND | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. | Negative | EC20 | 36 |
| RESPIRATION | ND | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. | Negative | EC20 | 36 |
| OXYGEN CONSUMPTION RATE (OCR) | > 100 μM | 2 minutes | human | HepG2 | Measurement of OCR | decrease | EC50 | 7 |
| ELECTRON TRANSPORT CHAIN | decrease | 35 | ||||||
| ELECTRON TRANSPORT CHAIN | decrease | 41 | ||||||
| ECAR | > 100 μM | 2 minutes | human | HepG2 | Measurement of ECAR | increase | EC50 | 7 |
| GLUCOSE GALACTOSE IC50 RATIO | 300.0 ± 0, 183.3 ± 2.9, 1.6, 300.0 ± 0, 205.3 ± 82.4 ,1.6 | 4hr | H9c2 cells | high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). | Negative | glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) | 50 | |
| GLUCOSE GALACTOSE IC50 RATIO | 300.0 ± 0, 78.3 ± 24.8, 4.1, 266 ± 58.9 , 62.6 ± 27.3, 5 | 24hr | H9c2 cells | high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). | glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) | 50 | ||
| SWELLING | > 800 µM | 30 mins | mouse | liver mitochondria | swelling assay: Absorbance at 545 nm using a fluorescence multi-well plate reader (CaCl2 (50 µM) was considered as the 100% baseline for the swelling ) | increase | EC20 | 36 |
| Target | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| NADH:ubiquinone reductase | inhibitor | 35 | ||||||
| NADH:ubiquinone reductase | inhibitor | 41 | ||||||
| NADH:ubiquinone reductase | ND | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. | Negative | EC20 | 36 |
| Succinate dehydrogenase | ND | 60 mins | mouse | liver mitochondria | Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. | Negative | EC20 | 36 |
| Cytochrome c | > 400 µM | 30 mins | mouse | liver mitochondria | Cytochrome c release was evaluated using ELISA kit ( 20 µg/ml Alamethicin was used as 100% baseline) | release | EC20 | 36 |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Danger |
Aggregated GHS information provided by 66 companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H302 (83.33%): Harmful if swallowed [Warning Acute toxicity, oral] H312 (66.67%): Harmful in contact with skin [Warning Acute toxicity, dermal] H332 (72.73%): Harmful if inhaled [Warning Acute toxicity, inhalation] H360 (19.7%): May damage fertility or the unborn child [Danger Reproductive toxicity] H361 (77.27%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] H373 (18.18%): Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure] H413 (15.15%): May cause long lasting harmful effects to aquatic life [Hazardous to the aquatic environment, long-term hazard] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P260, P261, P264, P270, P271, P273, P280, P281, P301+P312, P302+P352, P304+P312, P304+P340, P308+P313, P312, P314, P322, P330, P363, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
 |
Danger |
H361: Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] H372: Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] H401: Toxic to aquatic life [Hazardous to the aquatic environment, acute hazard] H410: Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard] |
P201, P202, P260, P264, P270, P273, P281, P308+P313, P314, P391, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| .alpha.,.alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide | .alpha.,.alpha.-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide | 13311-84-7 |
| 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide | 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide | 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide # |
| 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propionamide | 3'-Trifluoromethyl-4'-Nitro-Isobutyranilide | 311F847 |
| 37209-54-4 | 4''-nitro-3''-trifluoromethylisobutyranilide | 4'-Nitro-3'-(trifluoromethyl)isobutyranilide |
| 4'-Nitro-3'-trifluoromethylisobutyramilide | 4'-Nitro-3'-trifluoromethylisobutyranilide | 4-Nitro-3-(trifluoromethyl)isobutyranilide |
| 76W6J0943E | A806562 | AB0005010 |
| AB00052188 | AB00052188-09 | AB00052188_10 |
| AB00052188_11 | AB02835 | AB1010911 |
| AC-24192 | ACMC-20hidt | AK499646 |
| AKOS001025465 | AKOS025243203 | BCP23006 |
| BDBM50131270 | BPBio1_000087 | BRD-K28307902-001-05-0 |
| BRN 2157663 | BSPBio_000079 | BSPBio_003122 |
| C07653 | C11H11F3N2O3 | CAS-13311-84-7 |
| CCG-39105 | CCRIS 7246 | CHEBI:5132 |
| CHEMBL806 | CPD000058187 | CS-2359 |
| CTK4B8363 | Cebatrol, veterinary | Chimax |
| D00586 | DB-042163 | DB00499 |
| DSSTox_CID_11121 | DSSTox_GSID_32004 | DSSTox_RID_78899 |
| DTXSID7032004 | DivK1c_000459 | Drogenil |
| EINECS 236-341-9 | ETHINYL ESTRADIOL) | EU-0100557 |
| Eulexin | Eulexin (TN) | Eulexine |
| F 9397 | F0663 | FT-0626493 |
| Flutamid | Flutamida | Flutamida [INN-Spanish] |
| Flutamide (Eulexin) | Flutamide (JP17/USP/INN) | Flutamide (pubertal study) |
| Flutamide USP25 | Flutamide [USAN:BAN:INN] | Flutamide [USAN:USP:INN:BAN] |
| Flutamide for system suitability, European Pharmacopoeia (EP) Reference Standard | Flutamide(Eulexin) | Flutamide, European Pharmacopoeia (EP) Reference Standard |
| Flutamide, United States Pharmacopeia (USP) Reference Standard | Flutamide, certified reference material, TraceCERT(R) | Flutamide,(S) |
| Flutamidum | Flutamidum [INN-Latin] | Flutamin |
| GTPL6943 | HMS1568D21 | HMS1921O16 |
| HMS2090I18 | HMS2092O14 | HMS2095D21 |
| HMS2230P19 | HMS3259I03 | HMS3261P15 |
| HMS3373C12 | HMS3655G22 | HMS3712D21 |
| HMS501G21 | HY-B0022 | Ham's F-12 medium |
| IDI1_000459 | J10037 | K-4175 |
| KBio1_000459 | KBio2_001690 | KBio2_004258 |
| KBio2_006826 | KBio3_002342 | KBioGR_001377 |
| KBioSS_001690 | KS-00000L22 | KS-5091 |
| LP00557 | LS-2105 | Lopac-F-9397 |
| Lopac0_000557 | MCULE-7498839065 | METHOXYCHLOR |
| MFCD00072009 | MKXKFYHWDHIYRV-UHFFFAOYSA-N | MLS000069634 |
| MLS001065596 | MLS002548892 | N-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)ISOBUTYRAMIDE |
| N1-[4-nitro-3-(trifluoromethyl)phenyl]-2-methylpropanamide | NC00451 | NCGC00015452-01 |
| NCGC00015452-02 | NCGC00015452-03 | NCGC00015452-04 |
| NCGC00015452-05 | NCGC00015452-06 | NCGC00015452-07 |
| NCGC00015452-08 | NCGC00015452-09 | NCGC00015452-10 |
| NCGC00015452-11 | NCGC00015452-12 | NCGC00015452-13 |
| NCGC00015452-14 | NCGC00015452-15 | NCGC00015452-16 |
| NCGC00015452-19 | NCGC00015452-20 | NCGC00091460-01 |
| NCGC00091460-02 | NCGC00091460-03 | NCGC00091460-04 |
| NCGC00091460-05 | NCGC00091460-06 | NCGC00091460-07 |
| NCGC00091460-08 | NCGC00091460-09 | NCGC00254495-01 |
| NCGC00259718-01 | NCGC00261242-01 | NFBA |
| NINDS_000459 | NK-601 | NSC 215876 |
| NSC-147834 | NSC-215876 | NSC-757817 |
| NSC147834 | NSC215876 | NSC757817 |
| Niftholide | Niftolide | Odyne |
| PUBERTAL FLUTAMIDE STUDY (PUBERTAL STUDIES OF VINCLOZOLIN | Pharmakon1600-01500995 | Prestwick0_000180 |
| Prestwick1_000180 | Prestwick2_000180 | Prestwick3_000180 |
| Prestwick_228 | Propanamide, 2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)- | Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]- |
| Propanamide,2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]- | Prostandril | PubChem13536 |
| Q-201131 | Q418669 | SAM002264612 |
| SBB006930 | SBI-0050540.P003 | SC-12180 |
| SCH13521 | SCHEMBL12932289 | SCHEMBL3934 |
| SMR000058187 | SPBio_000982 | SPBio_002000 |
| SPECTRUM1500995 | SR-01000075888 | SR-01000075888-1 |
| SR-01000075888-6 | SR-01000075888-7 | SR-01000075888-9 |
| ST058409 | SW196536-4 | Sch 13521 |
| Sch-13521 | Spectrum2_001201 | Spectrum3_001421 |
| Spectrum4_000829 | Spectrum5_001450 | Spectrum_001210 |
| Tox21_110154 | Tox21_110154_1 | Tox21_202169 |
| Tox21_300536 | Tox21_500557 | UNII-76W6J0943E |
| Z56755651 | ZINC3812944 | a,a,a-Trifluoro-2-methyl-4'-nitro- m-propionotoluidide |
| alpha,alpha,alpha-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide | alpha,alpha,alpha-trifluoro-2-methyl-4''-nitro-m-propionotoluidide | flutamide |
| m-Propionotoluidide, .alpha.,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro- | m-Propionotoluidide, 2-methyl-4'-nitro-.alpha.,.alpha.,.alpha.-trifluoro- | m-Propionotoluidide, 2-methyl-4'-nitro-alpha,alpha,alpha-triflouro- |
| m-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro- | m-Propionotoluidide, alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro- (8CI) | m-Propionotoluidide,.alpha.,.alpha.-trifluoro- |
| m-Propionotoluidide,.alpha.,.alpha.-trifluoro-2-methyl-4'-nitro- | m-propionotoluidide,alpha,alpha,alpha-trifluoro-2-methyl-4'-nitro | niftolid |
| s1908 |
1. Dykens et al. (2007)